Piper Sandler raised the firm’s price target on Prothena (PRTA) to $36 from $15 and keeps an Overweight rating on the shares. The firm recognizes the value of its partnered pipeline with lucrative potential across net sales royalties and milestone payments. Piper remains bullish on Prothena and believes that there is substantial upside opportunity heading into a catalyst-rich next 12 months-plus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: